Diisopropylcarbodiimide → US10251893, Cpd 221

HRID 592255

반응식

HRID 592255 반응식
[F:1][C:2]1[CH:7]=[C:6]([C:8]2[C:13]([CH3:14])=[CH:12][C:11]([CH2:15][C:16]([OH:18])=O)=[CH:10][N:9]=2)[CH:5]=[CH:4][N:3]=1.[N:19]1[CH:24]=[CH:23][CH:22]=[C:21]([C:25]2[CH:26]=[CH:27][C:28]([NH2:31])=[N:29][CH:30]=2)[N:20]=1.C(N=C=NC(C)C)(C)C>C(Cl)Cl>[F:1][C:2]1[CH:7]=[C:6]([C:8]2[C:13]([CH3:14])=[CH:12][C:11]([CH2:15][C:16]([NH:31][C:28]3[CH:27]=[CH:26][C:25]([C:21]4[N:20]=[N:19][CH:24]=[CH:23][CH:22]=4)=[CH:30][N:29]=3)=[O:18])=[CH:10][N:9]=2)[CH:5]=[CH:4][N:3]=1

참가 물질

5

반응물 3

HCID 12734DiisopropylcarbodiimideHCID 584476635-(Pyridazin-3-yl)pyridin-2-amineHCID 584476922-(2'-Fluoro-3-methyl-2,4'-bipyridin-5-yl)acetic acid

생성물 1

HCID 46927368US10251893, Cpd 221

시약·촉매·용매 1

HCID 6344Dichloromethane용매

실험 절차

To the mixture of 2-(2′-fluoro-3-methyl-2,4′-bipyridin-5-yl)acetic acid 193-2 (25 mg, 0.1 mmol) and 5-(pyridazin-3-yl)pyridin-2-amine 145-3 (17 mg, 0.1 mmol) in DCM (1 mL) was added N,N′-Diisopropylcarbodiimide (22 μL, 0.15 mmol) at room temperature. The mixture was stirred at room temperature for 24 hours. The solvent was removed by rotary evaporation and the residue was dissolved in DMSO and then purified by reverse-phase HPLC to give 2-(2′-fluoro-3-methyl-2,4′-bipyridin-5-yl)-N-(5-(pyrazin-2-yl)pyridin-2-yl)acetamide 221 as white solid. MS m/z 401.1 (M+1); 1H NMR 400 MHz (DMSO-d6) δ 11.09 (s, 1H), 9.17 (dd, 1H), 9.07 (d, 1H), 8.51 (dd, 1H), 8.46 (d, 1H), 8.28 (d, 1H), 8.25 (dd, 1H), 8.18 (d, 1H), 7.76 (m, 1H), 7.71 (d, 1H), 7.51 (m, 1H), 7.31 (s, 1H), 3.83 (s, 2H), 2.31 (s, 3H).

후처리

  1. customThe solvent was removed by rotary evaporation
  2. dissolutionthe residue was dissolved in DMSO
  3. custompurified by reverse-phase HPLC

출처 및 근거

ORD 기록
ord-78cea9b2d79b4c758311347b5103ae16
출처 데이터셋
uspto-grants-2016_01
특허 번호
US09238646B2

연결된 노트

불러오는 중…